Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Net Margin (2016 - 2025)

Historic Net Margin for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 13.32%.

  • Myriad Genetics' Net Margin fell 29600.0% to 13.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.53%, marking a year-over-year decrease of 344400.0%. This contributed to the annual value of 15.2% for FY2024, which is 197600.0% up from last year.
  • Per Myriad Genetics' latest filing, its Net Margin stood at 13.32% for Q3 2025, which was down 29600.0% from 155.09% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Net Margin registered a high of 14.7% during Q3 2021, and its lowest value of 155.09% during Q2 2025.
  • Its 5-year average for Net Margin is 23.81%, with a median of 15.87% in 2023.
  • As far as peak fluctuations go, Myriad Genetics' Net Margin soared by 570700bps in 2021, and later crashed by -1377400bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Net Margin stood at 4.73% in 2021, then crashed by -403bps to 23.79% in 2022, then skyrocketed by 33bps to 15.87% in 2023, then fell by -27bps to 20.18% in 2024, then surged by 34bps to 13.32% in 2025.
  • Its last three reported values are 13.32% in Q3 2025, 155.09% for Q2 2025, and 0.05% during Q1 2025.